Q-omics provides the consensus-scored ART4 profile across patient tissues and cancer cell-line models. ART4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ART4 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, ART4 RNA expression shows 18,843 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LUAD, and THCA as cancer lineages where ART4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ART4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ART4 survival associations across molecular data types. ART4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ART4 RNA expression–survival associations across cancer types. High ART4 expression shows unfavorable associations in MESO and KIRP, but favorable associations in LUAD, SKCM, HNSC and ACC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ART4 RNA expression.
This table summarizes ART4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ART4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ART4 shows lower tumor expression in THCA, LUAD, COAD, HNSC, LUSC and KIRP. The THCA box plot shows higher ART4 RNA expression in normal versus tumor tissue (log2 FC = −1.937, t-test p < 0.001).
This table shows molecular features associated with ART4 in patient tissues and cancer cell lines. In patient samples, ART4 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ART4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
